Structure Therapeutics Inc. - American Depositary Shares (GPCR)

This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

The analyst is closely watching MariTide, a potential monthly injection to treat obesity.

Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.

The company is working on a drug that mimics apelin, which is released following exercise.

The major indexes reclaimed key levels and many leaders flashed buy signals.

The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots.

Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.

GPCR stock results show that Structure Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

If you want to do well with biotech stocks, trade the anticipation of news. Here are three stocks to consider.

Eli Lilly is still a smart pick, but these two stocks could grow more in the near term.

The Nasdaq tumbled amid chip woes.

Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest clinical trial data.